KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Non-Current Assets (2016 - 2026)

Gsk has reported Non-Current Assets over the past 18 years, most recently at $60.8 billion for Q1 2026.

  • For Q1 2026, Non-Current Assets rose 13.29% year-over-year to $60.8 billion; the TTM value through Mar 2026 reached $60.8 billion, up 13.29%, while the annual FY2025 figure was $58.0 billion, 6.42% up from the prior year.
  • Non-Current Assets for Q1 2026 was $60.8 billion at Gsk, up from $58.0 billion in the prior quarter.
  • Over five years, Non-Current Assets peaked at $60.8 billion in Q1 2026 and troughed at $39.9 billion in Q1 2022.
  • A 5-year average of $51.4 billion and a median of $52.1 billion in 2024 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: plummeted 51.43% in 2022 and later rose 18.48% in 2023.
  • Year by year, Non-Current Assets stood at $46.2 billion in 2022, then rose by 8.46% to $50.1 billion in 2023, then grew by 8.81% to $54.5 billion in 2024, then grew by 6.42% to $58.0 billion in 2025, then grew by 4.84% to $60.8 billion in 2026.
  • Business Quant data shows Non-Current Assets for GSK at $60.8 billion in Q1 2026, $58.0 billion in Q4 2025, and $58.7 billion in Q3 2025.